On the Value of CNS, ANS and Behavioral Measures in Early Clinical Psychopharmacology
The ever increasing number of newly developed potentially psychoactive compounds since 1952 resulted in a need for screening methods in early clinical pharmacology. The quantitative analysis of the human scalp-recorded EEG in combination with certain statistical procedures (called “quantitative pharmaco-EEG”) along with psychometric methods has been proven to mediate valuable objective and quantitative information about the effect of psychotropic drugs on their target organ— the human brain — and on human behavior (Fink, 1969, Saletu, 1976; Grünberger and Saletu, 1980). It seems possible to predict 1) if; 2) how; 3) in which dosage; 4) at which time a new compound will act, which will be shown by an example of a recently performed pharmaco-EEG and psychometric study with temazepam—a relatively new benzodiazepine with the advantage of a short half life and lack of active metabolites.
KeywordsPlacebo Half Life Diazepam Haloperidol Imipramine
Unable to display preview. Download preview PDF.
- Saletu, B., 1976, “Psychopharmaka, Gehirntatigkeit und Schlaf”, Karger, Basel.Google Scholar